查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049608

放射性藥物市場報告：按產品類型、應用、最終用途和地區分類（2026-2034 年）

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球放射性藥物市場規模達61億美元。展望未來，IMARC Group預測，該市場在2026年至2034年間將以4.52%的複合年成長率成長，到2034年達到92億美元。放射性藥物市場成長的主要驅動力包括診斷影像技術的進步、慢性病發病率的上升以及世界各國政府推出的有利監管標準。

放射性藥物市場趨勢：

醫學影像技術的進步：

正子斷層掃描（PET）和單光子發射電腦斷層掃描（SPECT）等影像技術的進步顯著提升了放射性藥物的診斷能力。利用這些技術對於腫瘤學、神經病學和心臟病學等領域需要早期治療或預防措施的疾病的早期診斷至關重要。例如，2023年全球PET市場規模約為119.6萬美元。根據出版商的預測，目前全球PET市場預計將以5.33%的複合年成長率從2024年成長到2032年，到2032年達到約19.3億美元。這一成長歸功於影像技術的進步以及這些先進系統在全球醫療診斷領域的應用。

慢性病盛行率增加：

市場成長主要受放射性藥物需求增加的驅動，這與全球癌症、心血管疾病和神經系統疾病發生率的上升密切相關。這些疾病需要精準的影像診斷和標靶治療，加速了放射性藥物在臨床實務中的應用。根據美國疾病管制與預防中心（CDC）2020年的數據，美國報告了1,603,844例新增癌症病例和602,347例死亡病例。這意味著每10萬人新增癌症病例403例，癌症相關死亡144例。目前，放射性藥物正被廣泛應用於癌症的早期檢測和治療，從而推動市場成長。

有利的法規環境：

該行業深受政府政策和法規的影響。例如，根據美國國家醫學圖書館 (NLM) 的一份報告顯示，美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構為新研發的放射性藥物提供了快速有效的核准程序，從而刺激了創新和投資。此外，藥物分類的快速虛擬審查以及獲得孤兒藥 (ODD) 認定的經濟獎勵，也促使許多製藥公司積極進行新型放射性藥物療法的研發工作。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球放射性藥物市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品類型分類

  • 診斷核子醫學
  • 治療性核子醫學

第7章 市場區隔：依應用領域分類

  • 腫瘤學
  • 循環系統
  • 神經病學
  • 內分泌學
  • 其他

第8章 市場區隔：依最終用途分類

  • 醫院和診所
  • 研究機構
  • 診斷中心

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Advanced Accelerator Applications（Novartis AG）
    • Bayer AG
    • Bracco SpA
    • Cardinal Health Inc.
    • Curium Pharma
    • General Electric Company
    • IBA RadioPharma Solutions
    • Jubilant Pharma Limited
    • Lantheus Medical Imaging Inc
    • Nordion Inc.（Sotera Health）
    • NTP Radioisotopes SOC Ltd
    • PharmaLogic Holdings Corp.
    • Siemens AG
Product Code: SR112026A3906

The global radiopharmaceuticals market size reached USD 6.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 9.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.52% during 2026-2034.The radiopharmaceuticals market is primarily driven by the emerging technological advancements in imaging technology, the increasing incidences of chronic ailments, and the implementation of favorable regulatory standards by the government across the globe.

Radiopharmaceuticals Market Trends:

Technological Advancements in Imaging Technologies:

The advancements in imaging technologies, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), have highly enhanced the diagnostic nature of radiopharmaceuticals. It is vital in the early diagnosis of conditions that require early treatment or preventive measures in oncology, neurology, and cardiology, using these technologies. For instance, in 2023, the global market for positron emission tomography (PET) was valued at approximately $1.196.1 Million. Presently, the global positron emission tomography (PET) market is projected to grow to about $1.93 billion by 2032, with a compound annual growth rate (CAGR) of 5.33% from 2024 through 2032, according to forecasts by the publisher. The growth is attributed to advances in imaging technology and the implementation of these advanced systems in medical diagnostics across the world.

Increasing Prevalence of Chronic Diseases:

The market growth is driven by the increasing demand for radiopharmaceuticals due to the rising prevalence of cancer, cardiovascular diseases, and neurological disorders worldwide. These diseases necessitate accurate diagnostic imaging and focused therapeutics, prompting the utilization of radiopharmaceuticals in clinical practice. According to CENTERS for DISEASE CONTROL AND PREVENTION data in 2020, the United States witnessed the reporting of 1,603,844 new incidences of cancer and the unfortunate loss of 602,347 lives due to the disease. This equates to a rate of 403 new cancer cases and 144 cancer-related deaths per 100,000 individuals. Currently, radiopharmaceuticals are used in diagnostic and treatment applications necessary for the early detection and treatment of cancers, thus driving market growth.

Favorable Regulatory Environment:

The industry is significantly impacted by governmental actions and regulatory provisions. For instance, regulatory authorities such as the U.S. FOOD AND DRUG ADMINISTRATION (FDA) and the EUROPEAN MEDICINES AGENCY (EMA) present instant and effective procedures to approve newly developed radiopharmaceuticals encouraging innovation and investment as per the NATIONAL LIBRARY of MEDICINE. Besides this, the possibility of a rapid virtual review of drug classes, along with financial incentives for obtaining Orphan Drug Designation (ODD) status, motivates many pharmaceutical companies to engage in research and development (R&D) of new radiopharmaceutical therapies.

Radiopharmaceuticals Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on product type, application, and end use.

Breakup by Product Type:

  • Diagnostic Nuclear Medicine
  • Therapeutic Nuclear Medicine

Diagnostic nuclear medicine accounts for the majority of the market share

Diagnostic nuclear medicine refers to the administration of a diverse number of radiopharmaceuticals typically used for imaging. It incorporates different modalities such as positron emission tomography (PET). The same also applies to single-photon emission computed tomography (SPECT). Due to the observed increase in the prevalence of diseases including cancer, cardiac abnormalities, and other neuronal conditions, the diagnostic nuclear medicine market is bound to expand in the coming years. At present, the Government Medical College and Hospital (GMCH) and the Super Speciality Hospital (SSH) in Nagpur are preparing to elevate their diagnostic capabilities by launching a dedicated nuclear medicine department. The proposal for this department was approved by the District Planning Committee (DPC) this year with a 9.5 crore budget. Since the administrative part has been sorted, the construction of the department is to be initiated soon.

Breakup by Application:

  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others

Oncology holds the largest share of the industry

Oncology applications in radiopharmaceuticals are experiencing rising demand, facilitated by the rapid growth of the targeted cancer therapies and precision medicine market. Radiopharmaceuticals are crucial in the diagnosis, staging, and post-treatment evaluation of cancers through PET and SPECT scans, among other modalities. This is also attributed to the expanding radiation oncology market which is expected to reach US$ 14.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032 as stated by the research team. Apart from this, ongoing research and development efforts to improve the feasibility and safety of radiopharmaceuticals in oncology are anticipated to boost the momentum of the sector.

Breakup by End Use:

  • Hospitals and Clinics
  • Research Institutes
  • Diagnostic Centers

Diagnostic centers represent the leading market segment

Diagnostic centers represent the largest segment and are creating a favorable radiopharmaceuticals market outlook. The rising demand for nuclear imaging procedures to achieve an accurate diagnosis of various medical conditions resulted in the adoption of diagnostic centers. It uses various imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging to ensure a favorable patient outcome. Hence various key players are introducing advanced diagnostic technologies which is further expanding the radiopharmaceuticals market value. For instance, in December 2022, Polarean Imaging plc, a leading medical imaging technology company, announced that the U.S. Food and Drug Administration (FDA) approved XENOVIEW. It is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) to assess lung ventilation in adults and pediatric patients 12 years of age and older. XENOVIEW represents a new era of pulmonary medicine since it is the very first inhaled MRI hyperpolarized contrast agent. It makes it possible to obtain a novel visualization of lung ventilation without exposing the patient to ionizing radiation and its associated risks. It is administered via the Polarean HPX hyperpolarization system, XENOVIEW is dispensed in a single 10-15 second breath hold MRI practice.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest radiopharmaceuticals market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for radiopharmaceuticals.

North America is dominating the market due to the presence of strong healthcare infrastructure, high healthcare spending, technological advancements, and the presence of established players within the market with numerous product offerings. According to the CENTERS FOR MEDICARE & MEDICAID SERVICES, United States health care spending grew 4.1% to reach $4.5 trillion in 2022, faster than the increase of 3.2% in 2021. Moreover, in 2022, the insured share of the population reached 92% (a historic high) and private health insurance enrollment increased by 2.9 million individuals and Medicaid enrollment increased by 6.1 million individuals. In addition, high government funding and support, as well as an increasing prevalence of disease, are also driving the market growth. Hence, this promotes innovation within the sector and accelerates the introduction of new and effective products generating an increasing radiopharmaceuticals market growth rate.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Currently, key players in the radiopharmaceuticals market are involved in various strategic initiatives to sustain their market positions and footholds. These initiatives include research and development investments to develop and innovate new radiopharmaceutical products with enhanced efficacies and safety. In addition to research, development, and innovation, the companies are also involved in strategic collaborations and partnerships to expand their product pipeline and distribution networks. For instance, in November 2023, SHINE Technologies, a fusion technology company based in Wisconsin, has recently entered a long-term supply agreement with Nucleus RadioPharma to supply lutetium-177. A radioisotope is utilized in cancer treatment therapies, including those under development for neuroendocrine tumors, prostate cancer, and other solid tumors. For several years, SHINE will supply Lu-177 to support Nucleus RadioPharma's radioligand therapy (RLT) offerings, which target radiopharmaceutical treatments specifically designed for neuroendocrine tumors and prostate cancer. Some key players are also involved in enhancing and optimizing manufacturing production processes to meet the growing demand for radiopharmaceuticals in line with upcoming and existing regulatory standards.

Key Questions Answered in This Report

  • 1.What was the size of the global radiopharmaceuticals market in 2025?
  • 2.What is the expected growth rate of the global radiopharmaceuticals market during 2026-2034?
  • 3.What has been the impact of COVID-19 on the global radiopharmaceuticals market?
  • 4.What are the key factors driving the global radiopharmaceuticals market?
  • 5.What is the breakup of the global radiopharmaceuticals market based on the product type?
  • 6.What is the breakup of the global radiopharmaceuticals market based on the application?
  • 7.What is the breakup of the global radiopharmaceuticals market based on the end use?
  • 8.What are the key regions in the global radiopharmaceuticals market?
  • 9.Who are the key players/companies in the global radiopharmaceuticals market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Radiopharmaceuticals Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Diagnostic Nuclear Medicine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Therapeutic Nuclear Medicine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Endocrinology
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Diagnostic Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Advanced Accelerator Applications (Novartis AG)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bracco S.p.A.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Cardinal Health Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Curium Pharma
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 General Electric Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 IBA RadioPharma Solutions
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Jubilant Pharma Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lantheus Medical Imaging Inc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Nordion Inc. (Sotera Health)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 NTP Radioisotopes SOC Ltd
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 PharmaLogic Holdings Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Siemens AG
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Radiopharmaceuticals Market: Major Drivers and Challenges
  • Figure 2: Global: Radiopharmaceuticals Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Radiopharmaceuticals Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Radiopharmaceuticals Market: Breakup by Product Type (in %), 2025
  • Figure 5: Global: Radiopharmaceuticals Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Radiopharmaceuticals Market: Breakup by End Use (in %), 2025
  • Figure 7: Global: Radiopharmaceuticals Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Radiopharmaceuticals (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Radiopharmaceuticals (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Radiopharmaceuticals (Cardiology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Radiopharmaceuticals (Cardiology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Radiopharmaceuticals (Neurology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Radiopharmaceuticals (Neurology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Radiopharmaceuticals (Endocrinology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Radiopharmaceuticals (Endocrinology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Radiopharmaceuticals (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Radiopharmaceuticals (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Radiopharmaceuticals (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Radiopharmaceuticals (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Radiopharmaceuticals (Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Radiopharmaceuticals (Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Radiopharmaceuticals (Diagnostic Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Radiopharmaceuticals (Diagnostic Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Radiopharmaceuticals Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Radiopharmaceuticals Market: Breakup by Country (in %), 2025
  • Figure 76: Middle East and Africa: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Radiopharmaceuticals Industry: SWOT Analysis
  • Figure 78: Global: Radiopharmaceuticals Industry: Value Chain Analysis
  • Figure 79: Global: Radiopharmaceuticals Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Radiopharmaceuticals Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Radiopharmaceuticals Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 3: Global: Radiopharmaceuticals Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Radiopharmaceuticals Market Forecast: Breakup by End Use (in Million USD), 2026-2034
  • Table 5: Global: Radiopharmaceuticals Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Radiopharmaceuticals Market: Competitive Structure
  • Table 7: Global: Radiopharmaceuticals Market: Key Players